AstraZeneca has completed all clinical studies required to support the first filings for the transition of its chronic ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket ... used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort, Breztri Aerosphere and Airsupra.

Starting with the Brestri Aerosphere COPD inhaler (pending regulatory approval), AstraZeneca intends to transition all of its MDIs to this technology by 2030. “The work we are doing with ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

15 At AstraZeneca, we are pursuing key pathways ... Exacerbations and real-world outcomes (EROS) among patients with COPD receiving single inhaler triple therapy of budesonide/glycopyrrolate ...

Dupixent’s success has highlighted the potential of biologics to target specific inflammatory pathways in COPD, a space previously dominated by inhaled therapies. AstraZeneca’s Fasenra ...